Incorporating Recently Approved Targeted Agents, Emerging Combinations, and Genetic Testing for the Optimal Management of Patients with Ovarian Cancer
Release Date: January 30, 2020
This activity will provide expert guidance regarding the use of currently-available therapies and companion diagnostics and will help clinicians plan for the optimal integration of new indications and combinations into practice when they become available.
The target audience for this activity is gynecologic oncologists, medical oncologists, advanced practitioners (NP/PA/PharmD) and other clinicians who treat patients with gynecologic malignancies.
After completing this activity, participants should be better able to:
- Assess the efficacy and safety of PARP inhibitors or their combinations in the maintenance and treatment setting for the management of patients with ovarian cancer
- Evaluate the various genetic testing platforms and their utility in identifying appropriate patients for platinum-based therapy and PARP inhibitor therapy
- Develop strategies for the optimal utilization of PARP inhibitors when managing patients with ovarian cancer
- Review novel agents that are under investigation for the treatment of platinum-resistant ovarian cancer
Method of Participation
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Materials will be available online through January 30, 2021.
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education, the University of Nebraska Medical Center, College of Nursing Continuing Nursing Education, and the American Nurses Credentialing Center’s Commission on Accreditation must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education, the University of Nebraska Medical Center, College of Nursing Continuing Nursing Education, and the American Nurses Credentialing Center’s Commission on Accreditation activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
All conference faculty and planning committee members have no conflicts to disclose with the exception listed in this activity.
All disclosed conflicts of interest have been resolved by independent content review.
This program may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education, the University of Nebraska Medical Center, College of Nursing Continuing Nursing Education, or the American Nurses Credentialing Center’s Commission on Accreditation or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
Thomas Herzog, MD
Deputy Director, University of Cincinnati Cancer Institute
Paul & Carolyn Flory Professor, Vice-Chair of Quality & Safety
Department of Obstetrics & Gynecology
University of Cincinnati
Advisory Board: AstraZeneca, Caris Life Sciences, Clovis Oncology, Inc., F. Hoffman-La Roche, Tesaro, a GSK Company
Disclosure of Off-Label Use
No product purposes, other than those approved by the FDA, will be discussed.
This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
This activity is supported by educational grants from AstraZeneca, Clovis Oncology, Inc., and Tesaro, a GSK Company
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.